Biocept (BIOC) stock price, revenue, and financials

Biocept market cap is $50.8 m, and annual revenue was $27.46 m in FY 2020

$50.8 M

BIOC Mkt cap, 14-Sept-2021

$17.8 M

Biocept Revenue Q1, 2021
Biocept Gross profit (Q1, 2021)8.8 M
Biocept Gross profit margin (Q1, 2021), %49.3%
Biocept Net income (Q1, 2021)2.6 M
Biocept EBIT (Q1, 2021)2.7 M
Biocept Cash, 31-Mar-202114.2 M
Biocept EV38.4 M
Get notified regarding key financial metrics and revenue changes at BioceptLearn more
Banner background

Biocept Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

5.1m3.3m5.5m27.5m

Revenue growth, %

(36%)

Cost of goods sold

6.9m9.3m10.1m11.0m21.3m

Gross profit

(4.3m)(6.8m)(5.4m)6.1m

Gross profit Margin, %

(84%)(209%)(99%)22%

Sales and marketing expense

5.1m6.3m5.9m5.9m6.4m

R&D expense

2.7m3.4m4.5m4.7m5.2m

General and administrative expense

6.6m7.2m7.1m7.0m10.0m

Operating expense total

21.2m26.2m27.5m17.6m21.6m

EBIT

(18.0m)(21.2m)(24.3m)(23.1m)(15.5m)

EBIT margin, %

(418%)(746%)(417%)(56%)

Interest expense

525.9k482.6k311.0k

Pre tax profit

(18.4m)(21.6m)(24.6m)(25.1m)(17.8m)

Income tax expense

2.1k7.6k(1.9k)

Net Income

(18.4m)(21.6m)(25.2m)(25.1m)(17.8m)

Biocept Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

4.6m2.1m3.4m9.3m14.4m

Accounts Receivable

129.0k1.2m1.6m3.5m14.1m

Prepaid Expenses

296.1k2.2m

Inventories

484.6k498.7k587.2k768.0k1.9m

Current Assets

5.8m4.3m6.0m13.9m32.6m

PP&E

3.1m2.7m1.5m2.3m

Total Assets

7.6m7.4m8.8m17.7m47.5m

Accounts Payable

960.5k1.3m2.0m2.0m8.4m

Short-term debt

842.5k

Current Liabilities

4.4m4.7m4.6m5.6m12.5m

Long-term debt

973.2k1.5m

Non-Current Liabilities

973.2k

Total Debt

1.8m1.5m

Total Liabilities

6.9m6.1m5.7m6.5m23.8m

Common Stock

5.5k1.3k

Additional Paid-in Capital

174.3m196.5m223.5m256.9m287.2m

Retained Earnings

(173.6m)(195.2m)(220.5m)(245.7m)(263.5m)

Total Equity

658.7k1.3m3.0m11.2m23.7m

Financial Leverage

11.5 x5.7 x2.9 x1.6 x2 x

Biocept Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(18.4m)(21.6m)(24.6m)(25.1m)(17.8m)

Depreciation and Amortization

322.0k575.7k800.9k931.7k1.1m

Accounts Receivable

(94.8k)(1.1m)(380.9k)(2.0m)(10.6m)

Inventories

494.7k100.9k(50.0k)(194.9k)(1.4m)

Accounts Payable

332.7k349.9k601.9k14.8k4.5m

Cash From Operating Activities

(15.7m)(19.7m)(22.4m)(23.0m)(19.8m)

Purchases of PP&E

(735.3k)(866.8k)

Cash From Investing Activities

(451.4k)(1.4m)(145.3k)(735.3k)(866.8k)

Long-term Borrowings

(932.9k)(1.5m)

Cash From Financing Activities

11.9m18.6m23.8m29.7m25.7m

Net Change in Cash

5.9m5.1m

Interest Paid

358.6k358.5k605.5k250.0k236.5k

Income Taxes Paid

2.1k5.3k4.5k

Biocept Ratios

USDFY, 2016

Financial Leverage

11.5 x

Biocept Employee Rating

3.97 votes
Culture & Values
4.3
Work/Life Balance
2.9
Senior Management
3
Salary & Benefits
3.1
Career Opportunities
2.5
Source